close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

9.08 8.74

Strong Buy

Prijsupdate 17 feb 2026, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.18

Max

9.91

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-3.82

Winstmarge

-75.213

Werknemers

279

EBITDA

1.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+94.29% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

116M

Vorige openingsprijs

0.34

Vorige sluitingsprijs

9.08

Nieuwssentiment

By Acuity

18%

82%

35 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 feb 2026, 23:44 UTC

Populaire aandelen

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

DJ

Lezen

17 feb 2026, 23:20 UTC

Winsten

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

DJ

Lezen

17 feb 2026, 22:57 UTC

Winsten

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

DJ

Lezen

17 feb 2026, 21:59 UTC

Winsten

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

DJ

Lezen

17 feb 2026, 23:54 UTC

Marktinformatie

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

DJ

Lezen

17 feb 2026, 23:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

17 feb 2026, 23:54 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

17 feb 2026, 23:45 UTC

Marktinformatie

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

DJ

Lezen

17 feb 2026, 23:19 UTC

Winsten

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Lezen

17 feb 2026, 23:15 UTC

Winsten

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Lezen

17 feb 2026, 22:58 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

DJ

Lezen

17 feb 2026, 22:58 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

DJ

Lezen

17 feb 2026, 22:57 UTC

Acquisities, Fusies, Overnames

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

DJ

Lezen

17 feb 2026, 22:50 UTC

Acquisities, Fusies, Overnames

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

DJ

Lezen

17 feb 2026, 22:44 UTC

Winsten

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Lezen

17 feb 2026, 22:42 UTC

Winsten

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

DJ

Lezen

17 feb 2026, 22:36 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

DJ

Lezen

17 feb 2026, 22:36 UTC

Winsten

Santos Final Dividend 10.3 U.S. Cents/Security

DJ

Lezen

17 feb 2026, 22:36 UTC

Winsten

Santos FY Underlying Profit US$898 Million, Down 25%

DJ

Lezen

17 feb 2026, 22:35 UTC

Winsten

Santos FY Revenue US$4.94 Billion, Down 8%

DJ

Lezen

17 feb 2026, 22:35 UTC

Winsten

Correct: Santos FY Net Profit US$818 Million, Down 33%

DJ

Lezen

17 feb 2026, 22:35 UTC

Acquisities, Fusies, Overnames

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

DJ

Lezen

17 feb 2026, 22:34 UTC

Winsten

Santos FY Net Profit US$818 Billion, Down 33%

DJ

Lezen

17 feb 2026, 22:02 UTC

Acquisities, Fusies, Overnames

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

DJ

Lezen

17 feb 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

DJ

Lezen

17 feb 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

17 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

17 feb 2026, 21:49 UTC

Acquisities, Fusies, Overnames

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

DJ

Lezen

17 feb 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

DJ

Lezen

17 feb 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

94.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.67 USD  94.29%

Hoogste 23 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

35 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,036.37

↓-0.35%

JNJ

Johnson and Johnson

243.49

↑ +0.08%

ABBV

AbbVie Inc

232.69

↑ +0.55%

NVS

Novartis AG

166.17

↑ +2.06%

MRK

Merck & Co Inc.

121.6

↑ +0.22%
help-icon Live chat